Bristol Myers Squibb Company Announces Quarterly Dividend of $0.63 (NYSE:BMY)

Bristol Myers Squibb Company (NYSE:BMY) declared a quarterly dividend on Wednesday, September 16th. Shareholders of record on Friday, October 2nd will be given a dividend of 0.63 per share by the biopharmaceutical company on Monday, November 2nd. This represents a c) dividend on an annualized basis and a yield of 4.0%. The ex-dividend date is Friday, October 2nd.

Bristol Myers Squibb has increased its dividend by an average of 0.0%per year over the last three years and has raised its dividend every year for the last 17 years. Bristol Myers Squibb has a payout ratio of 41.5% meaning its dividend is sufficiently covered by earnings. Research analysts expect Bristol Myers Squibb to earn $6.44 per share next year, which means the company should continue to be able to cover its $2.52 annual dividend with an expected future payout ratio of 39.1%.

Bristol Myers Squibb Stock Performance

NYSE BMY traded down $0.18 on Wednesday, reaching $63.55. 9,448,703 shares of the company’s stock traded hands, compared to its average volume of 11,790,750. The firm has a market cap of $129.80 billion, a price-to-earnings ratio of 14.00, a P/E/G ratio of 0.31 and a beta of 0.23. The stock has a 50 day moving average price of $63.87 and a 200-day moving average price of $60.10. Bristol Myers Squibb has a fifty-two week low of $42.52 and a fifty-two week high of $68.64. The company has a debt-to-equity ratio of 1.89, a quick ratio of 1.38 and a current ratio of 1.53.

Bristol Myers Squibb (NYSE:BMY) last released its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share for the quarter, beating analysts’ consensus estimates of $1.60 by $0.44. The business had revenue of $12.97 billion during the quarter, compared to analyst estimates of $11.74 billion. Bristol Myers Squibb had a return on equity of 66.90% and a net margin of 18.87%.The company’s revenue was up 5.7% on a year-over-year basis. During the same quarter last year, the business posted $1.46 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. Equities research analysts predict that Bristol Myers Squibb will post 6.95 EPS for the current fiscal year.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company that discovers, develops and commercializes prescription medicines. Its portfolio includes therapies for cancer, blood disorders, cardiovascular disease, immune-mediated conditions and psychiatric disorders. Key products include Opdivo and Yervoy for oncology, Eliquis for reducing the risk of stroke and systemic embolism, Revlimid for certain blood cancers, and several other specialty medicines.

The company serves patients and healthcare providers in markets around the world, with operations and commercial activities spanning North America, Europe, Asia-Pacific and other international regions.